Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | CNR2 | P34972 | 10/20 | 0.48 |
| ▸ | CNR1 | P21554 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.47 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4170696 | 0.90 | CYP2C19 (0.73) | CYP2C19CNR2CNR1TSHRNR1H2 | |
| SCHEMBL4162431 | 0.88 | TSHR (0.55) | CYP2C19CNR2TSHRNR1H2NR1H3 | |
| SCHEMBL4168768 | 0.83 | RAB9A (0.50) | CYP2C19TSHRNR1H2NR1H3BCL2L1 | |
| SCHEMBL11136763 | 0.82 | CYP2C19 (1.00) | CYP2C19CNR2CNR1TSHRNR1H2 | |
| SCHEMBL11824339 | 0.81 | CYP2C19 (0.76) | CYP2C19CNR2CNR1TSHRNR1H2 | |
| SCHEMBL22537839 | 0.80 | CYP2C19 (0.73) | CYP2C19CNR2CNR1TSHRNR1H2 | |
| SCHEMBL11735496 | 0.78 | CYP2C19 (0.81) | CYP2C19CNR2CNR1TSHRNR1H2 | |
| SCHEMBL15159187 | 0.78 | CYP2C19 (0.89) | CYP2C19CNR2CNR1TSHRNR1H2 | |
| SCHEMBL4160244 | 0.77 | TSHR (0.59) | CYP2C19CNR2TSHRNR1H2NR1H3 | |
| SCHEMBL15456984 | 0.77 | CYP2C19 (0.88) | CYP2C19CNR2CNR1TSHRNR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088438-A1 | NEW TYROSINE DERIVATIVES AS PPARy MODULATORS | LABORATORIOS SALVAT, S.A. (ES) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088438-A1 | NEW TYROSINE DERIVATIVES AS PPARy MODULATORS | PPARG, PPARD, TYRO3 | CYP2C19 1337/4885CNR2 109/4885CNR1 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.